公开(公告)号：WO2016011083A1

公开(公告)日：2016-01-21

申请号：PCT/US2015/040453

申请日：2015-07-14

Applicant: IMMUNE DESIGN CORP.

Inventor： KENNEY, Richard ,  HSU, Frank ,  TER MEULEN, Jan Henrik ,  BERGLUND, Peter Lars Aksel

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K9/0019 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/55572 ,  C12N7/00 ,  C12N2740/15043 ,  C12N2740/16043 ,  C12N2770/36122

Abstract: Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject a robust immune response. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of a humoral immune response and/or cellular immune response is desired and beneficial.

Abstract translation: 本文提供的组合物和方法用于改善在受试者中诱导鲁棒免疫应答的双重免疫策略。 因此，所描述的方法可用于治疗和/或预防（即，降低发生的可能性或风险）不同的疾病，病症和病症，例如诱导体液免疫应答和/或细胞免疫应答的癌症和感染性疾病 是理想和有益的。

公开(公告)号：WO2014041189A1

公开(公告)日：2014-03-20

申请号：PCT/EP2013/069241

申请日：2013-09-17

Applicant: NOVARTIS AG ,  SIMARD, Nathalie ,  HORNE, Michael

Inventor： SIMARD, Nathalie ,  HORNE, Michael

IPC: C07K14/18 ,  A61K39/12 ,  G01N33/569

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55566 ,  C12N7/00 ,  C12N2770/36122 ,  C12N2770/36134

Abstract: This disclosure relates to reagents, methods for treating, diagnosing, and tracking diseases associated with salmon alphavirus.

Abstract translation: 本公开涉及用于治疗，诊断和跟踪与鲑鱼病毒相关的疾病的试剂，方法。

公开(公告)号：WO2013177133A3

公开(公告)日：2014-03-20

申请号：PCT/US2013041980

申请日：2013-05-21

Applicant: UNIVERISITY OF CALIFORNIA

Inventor： DOWDY STEVEN F ,  YOSHIOKA NAOHISA

IPC: C12N15/40 ,  C12N5/074 ,  C12N5/10 ,  C12N15/85

CPC classification number: C12N5/0696 ,  C07K14/4702 ,  C07K14/4705 ,  C12N9/127 ,  C12N15/86 ,  C12N2501/60 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/605 ,  C12N2501/606 ,  C12N2506/1307 ,  C12N2770/36122 ,  C12N2770/36143 ,  C12N2840/206 ,  G01N33/56966

Abstract: The disclosure provides methods and compositions useful for obtaining induced stem cells, methods of making and use thereof.

Abstract translation: 本公开提供了用于获得诱导的干细胞的方法和组合物，其制备和使用方法。

公开(公告)号：WO2012106403A2

公开(公告)日：2012-08-09

申请号：PCT/US2012023444

申请日：2012-02-01

Applicant: UAB RESEARCH FOUNDATION ,  FROLOV ILYA ,  FROLOVA ELENA

Inventor： FROLOV ILYA ,  FROLOVA ELENA

IPC: C12N7/00 ,  A61K35/76

CPC classification number: A61K39/12 ,  A61K35/76 ,  C07K14/005 ,  C07K14/1808 ,  C12N7/00 ,  C12N2770/36111 ,  C12N2770/36121 ,  C12N2770/36122 ,  C12N2770/36123 ,  C12N2770/36134 ,  G01N2333/181

Abstract: The present invention provides pseudoinfectious alphavirus particles and methods of making them and using them to produce an immune response to an alphavirus in a subject.

Abstract translation: 本发明提供假感染性α病毒颗粒及其制备方法并使用它们在受试者中产生对α病毒的免疫应答。

公开(公告)号：WO2011082388A2

公开(公告)日：2011-07-07

申请号：PCT/US2011000001

申请日：2011-01-03

Applicant: MEDIGEN INC ,  PUSHKO PETER ,  TRETYAKOVA IRINA ,  LUKASHEVICH IGOR

Inventor： PUSHKO PETER ,  TRETYAKOVA IRINA ,  LUKASHEVICH IGOR

IPC: A61K48/00

CPC classification number: A61K39/12 ,  A61K49/0004 ,  A61K2039/5254 ,  A61K2039/53 ,  C07K14/005 ,  C12N7/00 ,  C12N2770/36121 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36151

Abstract: Described herein are i-DNATM vectors and vaccines and methods for using the same. The i-DNATM generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

Abstract translation: 本文描述了i-DNATM载体和疫苗以及使用它们的方法。 i-DNATM在体外或体内真核细胞中产生致病RNA病毒特别是基孔肯雅病毒（CHIKV）的减毒活疫苗。 当iDNA被注射到疫苗接受者体内时，活的减毒病毒的RNA通过在受体组织中的体内转录产生。 这启动了疫苗接受者组织中子代减毒病毒的产生，以及引发针对野生型非减毒病毒的有效免疫应答。

公开(公告)号：WO2009141434A4

公开(公告)日：2010-01-14

申请号：PCT/EP2009056240

申请日：2009-05-22

Applicant: FIT BIOTECH OY ,  KIIVER KAJA ,  SIKUT REIN ,  TOOTS URVE ,  MOELDER TARMO ,  MAENNIK ANDRES ,  USTAV MART ,  KALDMA KATRIN

Inventor： KIIVER KAJA ,  SIKUT REIN ,  TOOTS URVE ,  MOELDER TARMO ,  MAENNIK ANDRES ,  USTAV MART ,  KALDMA KATRIN

IPC: A61K39/39 ,  A61P37/04

CPC classification number: A61K39/39 ,  A61K2039/53 ,  A61K2039/55516 ,  C07K14/005 ,  C07K2319/09 ,  C12N7/00 ,  C12N9/127 ,  C12N2710/20022 ,  C12N2770/36122

Abstract: The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today.

Abstract translation: 本发明涉及甲病毒复制酶，特别是塞米利奇森林病毒复制酶，或编码甲病毒复制酶的表达载体，所述甲病毒复制酶包含RNA依赖性RNA聚合酶活性，用作免疫系统调节佐剂。 甲病毒复制酶可以与提供其中的佐剂功能的疫苗组合使用，当其中存在时，其将在给予该组合的受试者中产生额外的促进作用，与将单独的疫苗施用于 有需要的科目。 本发明的目的是提供一种有效和易于施用的与物种无关的佐剂，其将为今天与疫苗一起使用的佐剂提供优点。

公开(公告)号：WO2008026225A3

公开(公告)日：2008-09-25

申请号：PCT/IN2007000383

申请日：2007-08-31

Applicant: BHARAT BIOTECH INT LTD ,  ELLA KRISHNA MURTHY ,  SUMATHY KANDASWAMY ,  PYDIGUMMALA JAYA SHEELA ,  HEDGE NAGENDRA R

Inventor： ELLA KRISHNA MURTHY ,  SUMATHY KANDASWAMY ,  PYDIGUMMALA JAYA SHEELA ,  HEDGE NAGENDRA R

IPC: A61K39/12 ,  C07K14/18 ,  C12N7/02 ,  C12N7/06

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K2039/5252 ,  C12N7/00 ,  C12N2710/14143 ,  C12N2770/36122 ,  C12N2770/36134 ,  C12N2770/36151 ,  C12N2770/36163

Abstract: The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus.

Abstract translation: 本发明涉及能够在人和其他哺乳动物宿主中引发针对基孔肯雅病毒感染的保护性免疫应答的疫苗制剂。 免疫原性制剂包含稳定制剂中的纯化的灭活基孔肯雅病毒。 讨论了病毒繁殖和纯化的方法。 灭活的病毒制剂是非感染性的，免疫原性的并在哺乳动物宿主中引起保护性免疫应答。 配制免疫原性组合物用于体内施用给人。 本发明还讨论了使用重组病毒蛋白作为免疫抗原开发亚单位疫苗的策略。 具有潜在免疫原性的重组病毒抗原可用于诊断病毒的存在。

公开(公告)号：WO2006105279A2

公开(公告)日：2006-10-05

申请号：PCT/US2006011617

申请日：2006-03-29

Applicant: UNIV NEW YORK ,  HURTADO ALICIA ,  MERUELO DANIEL

Inventor： HURTADO ALICIA ,  MERUELO DANIEL

IPC: A61K48/00

CPC classification number: C12N7/00 ,  A01K2267/0331 ,  A61K35/76 ,  C07K14/005 ,  C12N15/86 ,  C12N2770/36122 ,  C12N2770/36132 ,  C12N2770/36143 ,  C12N2770/36161 ,  C12N2840/203

Abstract: Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for producing the vectors, methods for treating mammals suffering from tumors and pharmaceutical formulations for use in the treatment methods.

Abstract translation: 本文公开了由野生型Ar-339辛德毕斯病毒制备的新的有缺陷的辛德比斯病毒载体，其在JT载体和共有的辛德比斯病毒序列之间以及JT和Ar-339载体之间具有复制酶和包膜蛋白的差异。 还公开了用于生产载体的质粒，用于生产载体的方法，用于治疗患有肿瘤的哺乳动物的方法和用于治疗方法的药物制剂。

公开(公告)号：WO2006031996A3

公开(公告)日：2006-07-06

申请号：PCT/US2005033062

申请日：2005-09-14

Applicant: M OF HIGHER EDUCATION UNIVERSI ,  BERGMAN IRA ,  WHITAKER-DOWLING PATRICIA

Inventor： BERGMAN IRA ,  WHITAKER-DOWLING PATRICIA

IPC: C12N15/09 ,  A61K38/00 ,  C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C12N7/00

CPC classification number: C12N7/00 ,  A61K35/13 ,  A61K48/00 ,  C07K14/005 ,  C07K2319/00 ,  C07K2319/33 ,  C12N15/86 ,  C12N2710/16743 ,  C12N2710/16745 ,  C12N2760/20222 ,  C12N2760/20262 ,  C12N2770/36122 ,  C12N2810/60 ,  C12N2810/80

Abstract: The present invention relates to viruses that are engineered to contain a surface ligand molecule which targets the virus to a cell of interest. In particular non-limiting embodiments, the cell of interest is desirably ablated and may be a cancer cell, an infected cell, a cell exhibiting a non-malignant proliferative disorder, or a cell of the immune system. Alternatively, the cell of interest is a target for gene therapy.

Abstract translation: 本发明涉及经改造含有将病毒靶向感兴趣细胞的表面配体分子的病毒。 在具体的非限制性实施方案中，感兴趣的细胞理想地被消融并且可以是癌细胞，感染的细胞，呈现非恶性增殖性病症的细胞或免疫系统的细胞。 或者，感兴趣的细胞是基因治疗的目标。

公开(公告)号：WO2003104468A1

公开(公告)日：2003-12-18

申请号：PCT/IE2003/000089

申请日：2003-06-09

Applicant: THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN ,  ATKINS, Gregory, Julian ,  MORRIS-DOWNES, Margaret Mary ,  JERUSALMI, Alan ,  SHEAHAN, Brian, J.

Inventor： ATKINS, Gregory, Julian ,  MORRIS-DOWNES, Margaret Mary ,  JERUSALMI, Alan ,  SHEAHAN, Brian, J.

IPC: C12N15/86

CPC classification number: C07K14/005 ,  A61K38/1841 ,  A61K38/2026 ,  A61K38/215 ,  A61K48/00 ,  C12N15/86 ,  C12N2770/36122 ,  C12N2770/36143

Abstract: A Semiliki Forest Virus based vector system for delivery to the central nervous system is described, as is its use as an expression system for delivery to the central nervous system and pharmaceutical compositions for use in drug delivery to the CNS.

Abstract translation: 描述了用于递送至中枢神经系统的基于Semiliki Forest Virus的载体系统，以及其用作递送至中枢神经系统的表达系统和用于向CNS递送药物的药物组合物的用途。